BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27609621)

  • 1. Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma.
    Majós C; Cos M; Castañer S; Pons A; Gil M; Fernández-Coello A; Macià M; Bruna J; Aguilera C
    AJNR Am J Neuroradiol; 2016 Dec; 37(12):2224-2230. PubMed ID: 27609621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
    Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
    Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
    Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
    Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
    Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioblastoma survival is better analyzed on preradiotherapy MRI than on postoperative MRI residual volumes: A retrospective observational study.
    De Barros A; Attal J; Roques M; Nicolau J; Sol JC; Charni S; Cohen-Jonathan-Moyal E; Roux FE
    Clin Neurol Neurosurg; 2020 Sep; 196():105972. PubMed ID: 32512407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
    Strauss SB; Meng A; Ebani EJ; Chiang GC
    Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
    Kim BR; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    PLoS One; 2016; 11(11):e0166096. PubMed ID: 27835666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
    Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
    AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes.
    Villanueva-Meyer JE; Han SJ; Cha S; Butowski NA
    J Neurooncol; 2017 Aug; 134(1):213-219. PubMed ID: 28567589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions.
    Kim SH; Cho KH; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST
    AJNR Am J Neuroradiol; 2019 Dec; 40(12):2052-2058. PubMed ID: 31727756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study.
    Ismail M; Hill V; Statsevych V; Huang R; Prasanna P; Correa R; Singh G; Bera K; Beig N; Thawani R; Madabhushi A; Aahluwalia M; Tiwari P
    AJNR Am J Neuroradiol; 2018 Dec; 39(12):2187-2193. PubMed ID: 30385468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact on survival of early tumor growth between surgery and radiotherapy in patients with de novo glioblastoma.
    De Barros A; Attal J; Roques M; Nicolau J; Sol JC; Cohen-Jonathan-Moyal E; Roux FE
    J Neurooncol; 2019 May; 142(3):489-497. PubMed ID: 30783874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
    Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression.
    Neal ML; Trister AD; Ahn S; Baldock A; Bridge CA; Guyman L; Lange J; Sodt R; Cloke T; Lai A; Cloughesy TF; Mrugala MM; Rockhill JK; Rockne RC; Swanson KR
    Cancer Res; 2013 May; 73(10):2976-86. PubMed ID: 23400596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients.
    Palmer JD; Bhamidipati D; Shukla G; Sharma D; Glass J; Kim L; Evans JJ; Judy K; Farrell C; Andrews DW; Wang ZW; Peiper SC; Werner-Wasik M; Shi W
    Am J Clin Oncol; 2019 May; 42(5):481-486. PubMed ID: 30973372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.